↓ Skip to main content

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

Overview of attention for article published in Investigational New Drugs, August 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

patent
54 patents

Readers on

mendeley
75 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
Published in
Investigational New Drugs, August 2012
DOI 10.1007/s10637-012-9866-y
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
United States 1 1%
Japan 1 1%
Unknown 73 97%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 18 24%
Student > Ph. D. Student 8 11%
Student > Doctoral Student 7 9%
Student > Bachelor 6 8%
Student > Master 5 7%
Other 11 15%
Unknown 20 27%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 20 27%
Agricultural and Biological Sciences 11 15%
Biochemistry, Genetics and Molecular Biology 6 8%
Immunology and Microbiology 6 8%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Other 6 8%
Unknown 22 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 September 2026.
All research outputs
#7,744,540
of 23,549,388 outputs
Outputs from Investigational New Drugs
#343
of 1,197 outputs
Outputs of similar age
#55,788
of 166,444 outputs
Outputs of similar age from Investigational New Drugs
#5
of 16 outputs
Altmetric has tracked 23,549,388 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,197 research outputs from this source. They receive a mean Attention Score of 4.8. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 166,444 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.